Sign In
Buy HIMS
$28.01
+0.500 (+1.82%)
At Close: Jun 04, 2026
Hims & Hers Expands in Europe With Acquisition of ZAVA
11:25am, Tuesday, 03'rd Jun 2025
Hims & Hers Health (HIMS) shares rose Tuesday after the health and wellness site announced it was expanding its reach into Europe by buying London-based digital health platform ZAVA. The price of the
Hims expands into Europe with Zava acquisition
11:17am, Tuesday, 03'rd Jun 2025
CNBC's Brandon Gomez reports on the latest news regarding Hims.
The Bull Market is Back: 3 Stocks to Buy Now (HIMS, APP, META)
11:06am, Tuesday, 03'rd Jun 2025
Hims & Hers Health, AppLovin and Meta Platforms all boast a litany of bullish catalysts driving their stock prices higher.
Why Hims & Hers Health, Inc. (HIMS) is a Top Momentum Stock for the Long-Term
10:56am, Tuesday, 03'rd Jun 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Hims & Hers expands into Europe with Zava acquisition
10:48am, Tuesday, 03'rd Jun 2025
Hims & Hers (NYSE:HIMS), a leading US-based health and wellness platform, is expanding into Europe via its acquisition of telehealth platform and online pharmacy Zava. The company said the acquisit
Hims & Hers stock rockets on news of European launch
09:15am, Tuesday, 03'rd Jun 2025
Hims & Hers Health (NYSE: HIMS) experienced a notable uptick in its stock price following the announcement of its planned acquisition of ZAVA, a prominent European digital health platform.
Bet on Winning DuPont Analysis & Pick 3 Top Stocks
08:46am, Tuesday, 03'rd Jun 2025
Do you have more faith in DuPont analysis than simple ROE calculation? Tap EverQuote (EVER), Hims & Hers Health (HIMS) and Sprouts Farmers Market (SFM).
Hims to acquire UK-based startup Zava as it expands international presence
07:20am, Tuesday, 03'rd Jun 2025
Telehealth platform Hims & Hers said on Tuesday it will acquire London-based startup Zava for an undisclosed amount, allowing it to launch its offerings in Germany, France and Ireland and reach more i
Hims & Hers Announces Plans to Acquire ZAVA, Accelerating Major European Growth Across the UK, Germany, France, and Ireland
07:15am, Tuesday, 03'rd Jun 2025
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced a significant step in its global expansion through its agreement to acq
Hims & Hers to acquire European telehealth platform in global expansion
07:00am, Tuesday, 03'rd Jun 2025
Hims & Hers Health announced Tuesday it will acquire European telehealth platform Zava. The deal will expand Hims' services to Ireland, France and Germany and will grow its active customer base by rou
Hims & Hers: Still Huge Potential Ahead
05:02am, Tuesday, 03'rd Jun 2025
Hims & Hers Health, Inc is a telehealth platform offering tailored health and wellness services, showing significant stock volatility recently. HIMS experienced a dramatic rise from $24.11 to $68.75 i
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
10:05am, Monday, 02'nd Jun 2025
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Hims & Hers: Peptide And Short Squeeze Are Coming!
03:37pm, Saturday, 31'st May 2025
Hims & Hers is evolving beyond its original focus, aggressively expanding into peptides and GLP-1, positioning itself as a leader in the biohacking and longevity markets. The company's strategic moves
What's Happening With HIMS Stock?
09:05am, Saturday, 31'st May 2025
Hims & Hers Health (NYSE: HIMS), a telehealth platform, experienced an 8% increase in its stock on Friday, May 30th, following the announcement of a 4% reduction in its workforce. This move comes as t
Hims to cut 4% of workforce amid ban on weight-loss drug copies
07:22pm, Friday, 30'th May 2025
Telehealth platform Hims & Hers said on Friday it will cut 68 employees, or about 4% of its workforce, as it adjusts to a U.S. ban on manufacturing mass copies of the weight-loss drug Wegovy.
